Skip to main content
. 2019 Jun 21;198(1):101–110. doi: 10.1111/cei.13314

Figure 2.

Figure 2

Interleukin (IL)‐1Ra treatment prevents myocardial dysfunction and ventricular enlargement. (a) Schema of the magnetic resonance imaging (MRI) study experimental design. Mice received either Lactobacillus casei cell‐wall extract (LCWE) or LCWE with IL‐1Ra, which was given daily for 6 consecutive days starting 1 day before LCWE injection. MRI analysis was performed at the indicated different time‐points. (b–d) Ventricular ejection fraction (b), end‐point diastolic (c) and ‐systolic (d) volume measured at days 7, 14 and 35 post‐LCWE injection by MRI studies. (e) Heart rate (beats per minute; bpm) measurement in phosphate‐buffered saline (PBS) control mice, LCWE‐injected mice and LCWE‐injected mice pretreated with IL‐1Ra at 7 days post‐LCWE‐injection. Data are presented as mean ± standard error of the mean (s.e.m.); n = 5–9 mice per group. *P < 0·05, **P < 0·01 and ***P < 0·001 by one and two‐way analysis of variance (ANOVA) with Tukey's post‐test analysis.